Advertisement
U.S. markets open in 2 hours 29 minutes
  • S&P Futures

    4,979.75
    -11.75 (-0.24%)
     
  • Dow Futures

    38,565.00
    -77.00 (-0.20%)
     
  • Nasdaq Futures

    17,525.50
    -81.75 (-0.46%)
     
  • Russell 2000 Futures

    2,003.10
    -7.10 (-0.35%)
     
  • Crude Oil

    76.55
    -0.49 (-0.64%)
     
  • Gold

    2,039.10
    -0.70 (-0.03%)
     
  • Silver

    23.11
    -0.02 (-0.09%)
     
  • EUR/USD

    1.0803
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    4.2750
    0.0000 (0.00%)
     
  • Vix

    15.68
    +0.26 (+1.69%)
     
  • GBP/USD

    1.2618
    -0.0008 (-0.06%)
     
  • USD/JPY

    150.0870
    +0.1610 (+0.11%)
     
  • Bitcoin USD

    50,970.77
    -1,324.20 (-2.53%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,650.53
    -68.68 (-0.89%)
     
  • Nikkei 225

    38,262.16
    -101.45 (-0.26%)
     

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

STOCKHOLM, Jan. 4, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has dosed the first patient with TNG348, a novel USP1 inhibitor. Tango received U.S. Food and Drug Administration clearance on its Investigational New Drug application for TNG348 in September 2023.

TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers. HRD+ cancers, including BRCA1/2 mutations, represent up to 50% of ovarian cancers, 25% of breast cancers, 10% of prostate cancers and 5% of pancreatic cancers. Tango is developing TNG348 from the preclinical USP1 program licensed from Medivir in 2020.

In the study, TNG348 will be evaluated both as single agent and in combination with olaparib (PARP-inhibitor) in patients with BRCA1/2-mutant and other HRD+ cancers. Preclinical data has shown synergistic effect with PARP inhibitors in PARP naïve models, including models with resistance to PARP inhibitors.

-     "The preclinical data generated by Tango for TNG348 is promising and dosing the first patient in a clinical study is encouraging for patients with HRD+ cancers. The efforts undertaken by Tango to develop TNG348 into a clinical-staged drug are impressive and we will continue to follow the clinical development of TNG348 with great anticipation," says Jens Lindberg, CEO of Medivir.

Under the licensing agreement, Medivir is entitled to multiple development and commercial milestone payments as well as royalties on future sales. Dosing the first patient in a clinical trial triggers a milestone payment.

For additional information, please contact;
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100.
E-mail: magnus.christensen@medivir.com

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

The following files are available for download:

 

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/medivirs-licensee-tango-therapeutics-has-dosed-the-first-patient-with-tng348-a-novel-usp1-inhibitor-in-a-phase-12-clinical-study-302026095.html

SOURCE Medivir

Advertisement